Investors Encouraged to Join Class Action Against Immutep Limited for Fraud Allegations

The Schall Law Firm, a leading national litigation firm representing shareholders' rights, is calling on investors of Immutep Limited to join a class action lawsuit initiated in response to alleged securities fraud. This legal action centers around the faulty disclosures made by Immutep during a time period of significant turmoil for the company.

Background of the Case

Immutep Limited, a biotech company trading on NASDAQ under the ticker symbol IMMP, is purportedly under scrutiny following claims that it violated multiple sections of the Securities Exchange Act of 1934. The allegations specifically relate to assertions made by the company that were found to be misleading and false. Investors who acquired securities between March 24, 2025, and March 12, 2026, are especially urged to participate, as they may have endured significant financial losses due to these misrepresentations.

The lawsuit emerges from the company’s misleading statements regarding the efficacy of its TACTI-004 trial for its investigational drug, eftilagimod alfa (often referred to as “efti”). As noted by the Schall Law Firm in the details of the complaint, Immutep had declared the trial results were indicative of